|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Also, we estimated the diagnostic usefulness of the heparanase concentration for disease recurrence prediction in breast cancer cases.
|
31566192 |
2019 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Specific Inhibition of Heparanase by a Glycopolymer with Well-Defined Sulfation Pattern Prevents Breast Cancer Metastasis in Mice.
|
30543095 |
2019 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
SIGNIFICANCE: This study reveals the role of heparanase in promoting obesity-associated breast cancer and provides a mechanistically informed approach to uncouple obesity and breast cancer in a rapidly growing population of obese patients.
|
31481501 |
2019 |
|
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Moreover, knockdown of heparanase or inhibition of its activity with JG6, a heparanase inhibitor, was sufficient to block the formation of cell clusters and suppress breast cancer metastasis.
|
29417941 |
2018 |
|
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Here, we examined the expression of heparanase in pairs of primary and the resulting distant metastases of breast carcinoma.
|
29464068 |
2018 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
4-HPR Is an Endoplasmic Reticulum Stress Aggravator and Sensitizes Breast Cancer Cells Resistant to TRAIL/Apo2L.
|
30061204 |
2018 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Insulin signaling is regarded as a major contributor to this phenomenon; much less is known about the role of heparan sulfate-degrading enzyme heparanase in the link between metabolic disorders and cancer.In the present study we analyzed clinical samples of breast carcinoma derived from diabetic/non-diabetic patients, and investigated effects of heparanase on insulin signaling in breast carcinoma cell lines, as well as insulin-driven growth of breast tumor cells.We demonstrate that heparanase activity leads to enhanced insulin signaling and activation of downstream tumor-promoting pathways in breast carcinoma cells.
|
28038446 |
2017 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
These findings suggested that ELE may be a promising agent targeting heparanase in the treatment of breast cancer.
|
28560389 |
2017 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
These results suggest that targeting heparanase might improve treatments for breast cancer patients.
|
28388549 |
2017 |
|
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Varieties of experiments indicated that heparanase mRNA is overexpressed in human tumors, including breast cancer, gastrointestinal tumors, and esophageal carcinomas.
|
27804885 |
2017 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Gene expression profiling leads to discovery of correlation of matrix metalloproteinase 11 and heparanase 2 in breast cancer progression.
|
26084486 |
2015 |
|
Breast Carcinoma
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
We detected levels of heparanase expression and DNA methylation patterns of its promoter in breast cancer cell lines (MCF-7 and MDA-MB-435) and clinical tissues, respectively.
|
24632672 |
2014 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The cDNA of the enzyme responsible for cleaving HS chains from proteoglycans, HPSE1, was cloned in the pEGFP-N1 plasmid and transfected into a breast cancer cell lineage.
|
24083474 |
2013 |
|
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In contrast, the HPSE levels in breast cancer with lymph node metastasis were the highest.
|
23415719 |
2013 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our study implies that overexpression of EcSOD is a promising strategy to enhance the efficacy of heparin/LMWH by inhibiting heparanase as a novel treatment for breast cancer.
|
19602586 |
2009 |
|
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
A highly significant correlation (P<0.0001) between estrogen receptor (ER) positivity and heparanase overexpression was found in breast cancer.
|
17634531 |
2007 |
|
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Immunocytochemistry analysis demonstrated that heparanase was expressed in lymphocytes of breast cancer PBMC.
|
17603633 |
2007 |
|
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The siRNA targeting human heparanase almost completely inhibited the expression of heparanase in human breast carcinoma MDA-MB-435 cells, whereas the mismatched siRNA showed no effect.
|
17457040 |
2007 |
|
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Heparanase (HPR) is overexpressed in breast cancer but downregulated in differentiated normal tissue.
|
16271435 |
2006 |
|
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Our results indicate that heparanase expression increases during the progression of breast cancer into invasive cancer, and that this change is accompanied by increased COX-2 expression.
|
16391819 |
2006 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
CTD_human |
They also suggest that heparanase may play a novel role for COX-2 mediated tumor angiogenesis in breast-cancer progression.
|
16391819 |
2006 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Applying cell fractionation, Western blot analysis, determination of heparanase activity and confocal microscopy, we identified heparanase within the nuclei of human glioma and breast carcinoma cells and estimated its amount to be about 7% of the cytosolic enzyme.
|
15034597 |
2004 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Human breast carcinoma (MDA-MB-435) and mouse lymphoma (Eb) and melanoma (B16-BL6) tumor cell lines, which have naturally high levels of endogenous heparanase or have been genetically engineered to overexpress heparanase, were transfected with anti-heparanase ribozyme or siRNA.
|
15316057 |
2004 |
|
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Regulation of heparanase gene expression by estrogen in breast cancer.
|
14695198 |
2003 |